Eli Samaha buys 7.8 million worth of Theravance Biopharma stock - Investing.com

TBPH Stock  USD 9.25  0.17  1.80%   
Under 70% of Theravance Biopharma's investor base is looking to short. The analysis of overall sentiment of trading Theravance Biopharma stock suggests that many investors are alarmed at this time. Theravance Biopharma's investing sentiment shows overall attitude of investors towards Theravance Biopharma.
  
Eli Samaha buys 7.8 million worth of Theravance Biopharma stock Investing.com

Read at news.google.com
Google News at Macroaxis
  

Theravance Biopharma Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Theravance Biopharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Theravance Biopharma Fundamental Analysis

We analyze Theravance Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Theravance Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Theravance Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Theravance Biopharma is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Theravance Biopharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Theravance Biopharma stock to make a market-neutral strategy. Peer analysis of Theravance Biopharma could also be used in its relative valuation, which is a method of valuing Theravance Biopharma by comparing valuation metrics with similar companies.

Peers

Theravance Biopharma Related Equities

CTMXCytomX Therapeutics   3.92   
0%
41.0%
CNTBConnect Biopharma   2.91   
0%
30.0%
OVIDOvid Therapeutics   2.70   
0%
28.0%
ASMBAssembly Biosciences   1.25   
0%
13.0%
ACHLAchilles Therapeutics   0.93   
0%
9.0%
NUVBNuvation Bio   0.35   
0%
3.0%
NXTCNextCure   2.50   
26.0%
0%
SNSESensei Biotherapeutics   3.57   
38.0%
0%
TILInstil Bio   9.39   
100.0%
0%

Complementary Tools for Theravance Stock analysis

When running Theravance Biopharma's price analysis, check to measure Theravance Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theravance Biopharma is operating at the current time. Most of Theravance Biopharma's value examination focuses on studying past and present price action to predict the probability of Theravance Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theravance Biopharma's price. Additionally, you may evaluate how the addition of Theravance Biopharma to your portfolios can decrease your overall portfolio volatility.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
FinTech Suite
Use AI to screen and filter profitable investment opportunities